UTHR - United Therapeutics Corporation
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $6.78
|
Rev Est: $811.4M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$550.67
DETAILS
HIGH:
$645.00
LOW:
$447.00
MEDIAN:
$550.00
CONSENSUS:
$550.67
UPSIDE:
16.31%
Market Cap:
21.41B
Volume:
335,887
Avg Volume:
378,893
52 Week Range:
266.98-519.99
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.86
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
1,305
IPO Date:
1999-06-17
EPS (TTM):
26.44
P/E Ratio:
13.34
Revenue (TTM):
2.88B
Total Assets:
7.36B
Total Debt:
300.00M
Cash & Equiv:
1.70B
Rev Growth (5Y):
14.7%
EPS Growth (5Y):
7.2%
FCF Growth (5Y):
14.0%
ROCE:
23.9%
Debt/Equity:
0.05
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-10-29 | $7.16 | $6.89 | +3.9% | $799.5M | $814.8M | -1.9% |
| 2025-07-30 | $6.41 | $7.29 | -12.1% | $798.6M | $801.9M | -0.4% |
| 2025-04-30 | $6.63 | $6.29 | +5.4% | $794.4M | $778.7M | +2.0% |
| 2025-02-26 | $6.19 | $6.40 | -3.3% | $735.9M | $734.7M | +0.2% |
| 2024-10-30 | $6.39 | $6.43 | -0.6% | $748.9M | $722.6M | +3.6% |
| 2024-07-31 | $5.85 | $6.40 | -8.6% | $714.9M | $691.9M | +3.3% |
| 2024-05-01 | $6.17 | $5.65 | +9.2% | $677.7M | $624.0M | +8.6% |
| 2024-02-21 | $4.36 | $4.19 | +4.1% | $614.7M | $575.9M | +6.7% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.88B | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.60B | 1.47B | 1.29B | 1.12B |
| Net Income | 1.20B | 984.80M | 727.30M | 475.80M | 514.80M | (104.50M) | 589.20M | 417.90M | 713.70M | 651.64M | 340.07M | 174.56M |
| EPS | 26.44 | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 | 14.17 | 7.06 | 3.49 |
| Total Assets | 7.36B | 7.17B | 6.04B | 5.17B | 4.62B | 3.91B | 3.40B | 2.88B | 2.33B | 2.18B | 1.88B | 2.09B |
| Total Debt | 300.00M | 700.00M | 800.00M | 800.00M | 800.00M | 850.00M | 250.00M | 250.00M | 0 | 5.39M | 126.41M | 286.18M |
| Cash & Equivalents | 1.70B | 1.21B | 961.20M | 894.80M | 738.70M | 738.40M | 669.20M | 705.10M | 1.02B | 831.80M | 397.70M | 278.89M |
| Operating Cash Flow | 1.33B | 978.00M | 802.50M | 598.20M | 755.70M | (206.60M) | 778.40M | 474.20M | 643.60M | 382.80M | 355.30M | 425.27M |
| Free Cash Flow | 1.08B | 747.60M | 663.70M | 477.40M | 696.40M | (290.30M) | 594.00M | 387.90M | 600.40M | 333.01M | 307.86M | 393.36M |
| FCF per Share | 23.91 | 15.97 | 14.59 | 10.63 | 15.76 | -6.63 | 13.66 | 8.82 | 13.71 | 7.24 | 6.39 | 7.86 |
| Book Value | 6.44B | 5.98B | 4.80B | 3.96B | 3.40B | 2.78B | 2.79B | 2.10B | 1.86B | 1.60B | 1.27B | 1.30B |
| Cash & ST Investments | 3.27B | 2.99B | 2.84B | 1.93B | 1.83B | 1.49B | 1.42B | 927.40M | 1.05B | 953.80M | 695.54M | 693.90M |
| ROC Equity | 0.19 | 0.16 | 0.15 | 0.12 | 0.15 | -0.04 | 0.21 | 0.20 | 0.38 | 0.41 | 0.27 | 0.13 |